Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

We came across a bullish thesis on Schrödinger, Inc. (SDGR) on Value Degen’s Substack by Unemployed Value Degen. In this ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Eli Lilly (LLY) stock gained as Citi resumed its covderage with a buy rating and $1,060 price target, citing optimism for its ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The ...

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral ...

Baron Funds mentioned Eli Lilly and Company (NYSE:LLY) in its Q2 2024 investor letter. Here is what the fund said: ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year target of Eli Lilly stock is $898, which is 3.96% lower than today’s price of $935.06. Of the 26 analysts ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- the year it was first approved in the U.S. -- some analysts predicted that ...